

TUESDAY, AUGUST **29**, 2017

**12:45 - 13:45 ROOM: SPOTLIGHT STAGE**

# **Baroreflex activation therapy: its role in the management of heart failure and resistant hypertension**

## **CHAIRS**

Stefan D. Anker, Berlin, Germany

Faiez Zannad, Nancy, France

## **SPEAKERS**

A. Pathak, Toulouse, France

Peter de Leeuw, Maastricht, The Netherlands

C. Butter, Bernau, Germany



SATELLITE SYMPOSIUM

Organised by Medical School

*Charité*

CHARITÉ  
UNIVERSITÄTSMEDIZIN BERLIN

Supported by an unrestricted  
grant provided by

**CVRx®**

TUESDAY, AUGUST 29, 2017

12:45 - 13:45 ROOM: SPOTLIGHT STAGE

PROGRAMME

**Baroreflex activation therapy: its role  
in the management of heart failure and  
resistant hypertension**

Welcome and Introduction

Chairs

Why is the baroreflex a relevant target for both  
resistant hypertension and heart failure?

A. Pathak, Toulouse, France

Resistant hypertension: stimulating  
the baroreflex when drugs have failed

Peter de Leeuw, Maastricht, The Netherlands

Heart Failure with reduced ejection fraction:  
how can baroreflex activation therapy help?

C. Butter, Bernau, Germany

EDUCATIONAL  
OBJECTIVES

- Assess the baroreflex as a primary regulator of cardiovascular function and have a better understanding of the rationale for Carotid Baroreceptor Stimulation
- Understand how specific management strategies can be applied in special populations of patients with resistant hypertension when drugs have failed.
- Review the data and experience with Baroreflex Activation Therapy in Heart Failure with reduced Ejection Fraction (HFrEF)

Organised by Medical School

*Charité*

CHARITÉ  
UNIVERSITÄTSMEDIZIN BERLIN

Supported by an unrestricted  
grant provided by

**CVRx®**